Tag Archives: forecast

Orphan Drug Market to Reach $176 Billion by 2020, Says Report

By 2020, orphan drugs are expected to account for 19 percent of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to EvaluatePharma’s Orphan Drug Report 2014. At 11 percent, this growth is set to be more than double the 5 percent growth rate of the overall prescription market, […]
Posted in Global, Orphan Drugs | Also tagged , , | Leave a comment

Japan’s Non-Hodgkin Lymphoma Market to Top $1 Billion by 2020

The Non-Hodgkin Lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia, China and Japan will expand from $1.1 billion in 2013 to $1.7 billion by 2020, with Japan remaining the largest contributor to growth, according to GBI Research. The company’s new report says that Japan had a 67.2% share of the APAC […]
Posted in Global, healthcare | Also tagged , , , , , | Leave a comment

Mexico’s Healthcare Market Value “to Reach Almost $28 Billion by 2020″

Mexico’s pharmaceutical industry will be worth approximately US$22.5 billion by 2020, according to research and consulting firm GlobalData. Combined with the medical devices industry — expected to be worth US$5.4 billion by the same time — the total value of Mexico’s healthcare market value will be $27.9 billion. GlobalData reports that this overall increase in Mexico’s […]
Posted in Emerging Markets, Global | Also tagged , , | Leave a comment

New "Blockbusters" Will Triple Acute Coronary Syndrome Market

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Posted in Global, Strategy | Also tagged , , , , , , | Leave a comment

Pharm Exec's 2014 Dealmakers Outlook

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast […]
Posted in Deals, Global, Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta